Figure S7 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
Year: 2023
Type: other
Abstract: Canine primary lung cancer cell line sensitivity to lapatinib. Four canine cell lines (three HER2WT and one HER2V659E) were treated with 14 lapatinib doses ranging from 100 μM to 5.5x10-2 nM for 72 hours with CellTiterGlo viability endpoints were measured and shown as percent survival relative to DMSO vehicle control.
Authors: Gwendolen Lorch, Karthigayini Sivaprakasam, Victoria Zismann, Nieves Perdigones, Tania Contente-Cuomo, Alexandra Nazareno, Salvatore Facista, Shukmei Wong, Kevin Drenner, Winnie S. Liang, Joseph M. Amann, Sara L. Sinicropi-Yao, Michael J. Koenig, Krista La Perle, Timothy G. Whitsett, Muhammed Murtaza, Jeffrey M. Trent, David P. Carbone, William P.D. Hendricks
Language: English
Topic: Veterinary Oncology Research
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361936825